Citizens raised the firm’s price target on Option Care Health (OPCH) to $38 from $36 and keeps an Outperform rating on the shares. 2026 should represent the final year of any meaningful Stelara-related profit headwinds, given Stelara and its related biosimilars now represent under 1% of gross profit, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- Closing Bell Movers: Revvity up 9% on strong outlook
- Option Care Health Issues 2025 Results and 2026 Outlook
- Option Care Health raises FY25 adjusted EPS view to $1.72-$1.76 from $1.68-$1.72
- Option Care Health sees FY26 adjusted EPS $1.82-$1.92, consensus $1.88
- Option Care Health increases share repurchase program to $1B